Ignite Creation Date:
2025-12-25 @ 5:08 AM
Ignite Modification Date:
2026-05-21 @ 9:39 PM
Study NCT ID:
NCT04811027
Status:
COMPLETED
Last Update Posted:
2025-12-11
First Post:
2021-03-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
Sponsor:
Immutep S.A.S.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
TACTI-003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |